Neuroaptamer

Neuroaptamer group members publications:


Cussell, P.J.G., Howe, M.S., Illingworth, T.A., Gomez Escalada, M., Milton, N.G.N. & Paterson, A.W.J. (2019) The formyl peptide receptor agonist FPRa14 induces differentiation of Neuro2a mouse neuroblastoma cells into multiple distinct morphologies which can be specifically inhibited with FPR antagonists and FPR knockdown using siRNA. PLoS ONE 14(6), e0217815.

Werner, S.J., Martin, S.W., Paterson, A.W.J. & Milton, N.G.N. (2018) Effects of the cannabinoid receptor antagonist hemopressin on amyloid-β induced toxicity in mouse Neuro-2a neuroblastoma cells. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol18Issue1abst224P.pdf

Cussell, P.J., Howe, M.S., Gomez Escalada, M., Milton, N.G.N. & Paterson, A.W.J. (2018) Formyl peptide receptor agonist FPRa14 induced differentiation of Neuro2a mouse neuroblastoma cells in culture. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol18Issue1abst228P.pdf

Milton, N.G.N. (2017) Effects of the CB1 cannabinoid receptor antagonist AM281 on kissorphin protection against amyloid-β neurotoxicity. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol17Issue1abst030P.pdf

Werner, S.J., Martin, S.W., Paterson, A.W.J. & Milton, N.G.N. (2017) Effects of RVD-hemopressin on amyloid-β induced toxicity in SH-SY5Y neuronal cell culture. Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol17Issue1abst020P.pdf

Milton, N. (2017) Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. United Kingdom Patent Publication Number GB 2493313 (B).

Chilumuri, A., Markiv, A. & Milton, N.G.N. (2014) Immunocytochemical staining of endogenous nuclear proteins with the HIS-1 anti-poly-histidine monoclonal antibody: apotential source of error in His-tagged protein detection. Acta Histochemica, 1161022-1028.

Milton, N.G.N. & Harris, J.R. (2014) Chapter 23 - Polymorphism of Amyloid Fibrils and their Complexes with Catalase. In: Bio-nanoimaging: Protein Misfolding and Aggregation. Eds V.N. Uversky & Y.L. Lyubchenko, Academic Press, Boston, pp 255-262.

Chilumuri, A., Odell, M. & Milton, N.G.N. (2013) Benzothiazole aniline-tetra(ethylene glycol) and 3-amino-1,2,4-triazole inhibit neuroprotection against amyloid peptides by catalase overexpression in vitro. ACS Chem. Neurosci.4, 1501-1512.

Chilumuri, A., Odell, M. & Milton, N. (2013) The neuroprotective role of catalase overexpression in SH-SY5Y cells against beta-amyloid and H2O2 toxicity. Alzheimer's & Dementia: The Journal of the Alzheimer's Association9 (4 (Supplement)), P361.

Chilumuri, A. & Milton, N.G.N. (2013) The role of neurotransmitters in protection against amyloid-β toxicity by KiSS-1 overexpression in SH-SY5Y neurons.ISRN Neuroscience, 2013, 253210.

Chilumuri, A., Ashioti, M., Nercessian, A.N. & Milton, N.G.N. (2013) Immunolocalization of kisspeptin associated with amyloid-ß deposits in the pons of an Alzheimer's disease patient. J. Neurodegen. Dis., 2013, 879710.

Milton, N. (2013) Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. United Kingdom Patent Application Publication Number GB 2493313 (A).

Milton, N.G.N. & Harris, J.R. (2013) Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide. Micron44, 246-253.

Harris, J.R. & Milton, N.G.N. (2012) Introduction and technical survey: protein aggregation and fibrillogenesis. Subcell. Biochem., 65, 3-25.

Milton, N.G.N. (2012) In vitro activities of Kissorphin, a novel hexapeptide KiSS-1 derivative, in neuronal cells. J. Amino Acids2012, 691463.

Milton, N.G.N., Chilumuri, A., Rocha-Ferreira, E., Nercessian, A.N. & Ashioti, M. (2012) Kisspeptin prevention of amyloid-ß peptide neurotoxicity in vitro. ACS Chem. Neurosci., 3, 706-719.

Milton, N. (2012) Kissorphin, a hexapeptide derivative of Kisspeptin, acts via Neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no Gonadotrophin-Releasing-Hormone releasing activity. Endocrine Abstracts28, OC2.3.

Milton, N. (2011) Kissorphin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. International Patent Application Publication Number WO 2011/144714 (A1).

Milton, N. (2011) Kisspeptin peptides for use in the treatment of Alzheimer's disease, Creutzfeldt-Jakob disease or diabetes mellitus. European Patent Application Publication Number EP2388012 (A1).

Milton, N.G.N. & Harris, J.R. (2010) Human islet amyloid polypeptide fibril binding to catalase: a transmission electron microscopy and microplate study. The Scientific World Journal, 10, 879-893.

Harris, J.R. & Milton, N.G.N. (2010) Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell. Biochem., 51, 47-75.

Milton, N.G.N. & Harris, J.R. (2009) Polymorphism of Amyloid-ß fibrils and its effects on Human Erythrocyte Catalase binding. Micron40, 800-810.

Milton, N.G.N. (2008) Homocysteine inhibits hydrogen peroxide breakdown by Catalase. The Open Enzyme Inhibition Journal1, 34-41.

Milton, N.G.N. (2006) Anti-sense Peptides. In Cell Biology Protocols, Eds D. Rickwood, J. Graham & J.R. Harris, Wiley, London, pp 353-358.

Milton, N.G.N. (2006) Interactions between amyloid-ß and enzymes. In Cell Biology Protocols, Eds D. Rickwood, J. Graham & J.R. Harris, Wiley, London pp 359-363.

Milton, N.G.N. (2006) Amyloid-ß phosphorylation. In Cell Biology Protocols, Eds D. Rickwood, J. Graham & J.R. Harris, Wiley, London pp 364-368.

Milton, N.G.N. (2005) Phosphorylated amyloid-ß: the toxic intermediate in Alzheimer's disease neurodegeneration. Subcell. Biochem., 38, 381-402.

Milton, N.G.N. (2005) Phosphorylated Amyloid-ß 1-43 protein and its use in the treatment of Alzheimer's disease. European Patent Application Publication Number EP1538163.

Milton, N.G.N. (2004) Role of hydrogen peroxide in the aetiology of Alzheimer's Disease: implications for treatment. Drugs Aging, 21, 81-100.

Milton, N.G.N. (2004) Peptides for use in the treatment of Alzheimer's disease. United States Patent Application Publication Number US 2004/0072753.

Vincent, I., Nagy, Z., Neve, R., Herrup, K., Milton, N., Smith, M., Wolozin, B., Chen, Y., Lu, K.P., Kinoshita, J., Strobel, G., Hallows, J., Bowser, R., Feinstein, D., Atwood, C., and Maiese, K. (2003) Transcript of Live Discussion: The Cell Cycle in Alzheimer's Disease: Let's Unite Around Division. J. Alzheimers Dis.5, 251-262.

Milton, N.G.N. (2003) Peptides for use in the treatment of Alzheimer's disease. European Patent Application Publication Number EP1363939.

Milton, N.G.N. (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-ß peptide. Neurosci. Lett., 332, 127-130.

Milton, N.G.N. (2002) The amyloid-ß peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity. Neurosci. Lett., 322, 131-133.

Milton, N.G.N. (2002) Peptides for use in the treatment of Alzheimer's disease. International Patent Application Publication Number WO 02/36614.

Milton, N.G.N. (2001) Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer’s amyloid-ß peptide. NeuroToxicology, 22, 767- 774.

Milton, N.G.N. (2001) Phosphorylation of amyloid-ß at the serine 26 residue by human cdc2 kinase. NeuroReport, 12, 3839-3844.

Milton, N.G.N., Mayor, N.P. & Rawlinson, J. (2001) Identification of amyloid-ß binding sites using an antisense peptide approach. NeuroReport12, 2561-2566.

Milton, N.G.N. (1999) Amyloid-ß binds catalase with high affinity and inhibits hydrogen peroxide breakdown. Biochem. J.344, 293-296.